| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Organogenesis Hldgs (NASDAQ:ORGO) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Organogenesis Hldgs missed estimated earnings by 0.0%, reporting an EPS of $0.01 versus an estimate of $0.01.
Revenue was down $15.87 million from the same period last year.
Last quarter the company beat on EPS by $0.04 which was followed by a 11.0% increase in the share price the next day.
Here's a look at Organogenesis Hldgs's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | 0 | 0.02 | -0.02 | 0.05 |
| EPS Actual | 0.04 | 0.05 | -0.01 | 0.07 |
| Revenue Estimate | 111.40M | 115.10M | 95.50M | 122.40M |
| Revenue Actual | 108.53M | 117.32M | 107.64M | 115.52M |
To track all earnings releases for Organogenesis Hldgs visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ORGO
